Sarah M Bartsch1, Peter J Hotez2, Daniel L Hertenstein1, David J Diemert3, Kristina M Zapf1, Maria Elena Bottazzi2, Jeffrey M Bethony3, Shawn T Brown4, Bruce Y Lee5. 1. Public Health Computational and Operational Research (PHICOR), Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA; Global Obesity Prevention Center, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA. 2. National School of Tropical Medicine, and Departments of Pediatrics and Molecular Virology & Microbiology, Baylor College of Medicine, One Baylor Plaza, BCM113, Houston, TX 77030, USA; Sabin Vaccine Institute, 2000 Pennsylvania Avenue NW, Washington, DC 20006, USA. 3. Sabin Vaccine Institute, 2000 Pennsylvania Avenue NW, Washington, DC 20006, USA; Department of Microbiology, Immunology and Tropical Medicine, The George Washington University Medical Center, Washington, DC 20037, USA. 4. Pittsburgh Supercomputing Center, Carnegie Mellon University, 300S Craig St, Pittsburgh, PA 15213, USA. 5. Public Health Computational and Operational Research (PHICOR), Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA; Global Obesity Prevention Center, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, USA. Electronic address: brucelee@jhu.edu.
Abstract
BACKGROUND: Although mass drug administration (MDA) has helped reduce morbidity attributed to soil-transmitted helminth infections in children, its limitations for hookworm infection have motivated the development of a human hookworm vaccine to both improve morbidity control and ultimately help block hookworm transmission leading to elimination. However, the potential economic and epidemiologic impact of a preventive vaccine has not been fully evaluated. METHODS: We developed a dynamic compartment model coupled to a clinical and economics outcomes model representing both the human and hookworm populations in a high transmission region of Brazil. Experiments simulated different implementation scenarios of MDA and vaccination under varying circumstances. RESULTS: Considering only intervention costs, both annual MDA and vaccination were highly cost-effective (ICERs ≤ $790/DALY averted) compared to no intervention, with vaccination resulting in lower incremental cost-effectiveness ratios (ICERs ≤ $444/DALY averted). From the societal perspective, vaccination was economically dominant (i.e., less costly and more effective) versus annual MDA in all tested scenarios, except when vaccination was less efficacious (20% efficacy, 5 year duration) and MDA coverage was 75%. Increasing the vaccine's duration of protection and efficacy, and including a booster injection in adulthood all increased the benefits of vaccination (i.e., resulted in lower hookworm prevalence, averted more disability-adjusted life years, and saved more costs). Assuming its target product profile, a pediatric hookworm vaccine drastically decreased hookworm prevalence in children to 14.6% after 20 years, compared to 57.2% with no intervention and 54.1% with MDA. The addition of a booster in adulthood further reduced the overall prevalence from 68.0% to 36.0% and nearly eliminated hookworm infection in children. CONCLUSION: Using a human hookworm vaccine would be cost-effective and in many cases economically dominant, providing both health benefits and cost-savings. It could become a key technology in effecting control and elimination efforts for hookworm globally.
BACKGROUND: Although mass drug administration (MDA) has helped reduce morbidity attributed to soil-transmitted helminth infections in children, its limitations for hookworm infection have motivated the development of a human hookworm vaccine to both improve morbidity control and ultimately help block hookworm transmission leading to elimination. However, the potential economic and epidemiologic impact of a preventive vaccine has not been fully evaluated. METHODS: We developed a dynamic compartment model coupled to a clinical and economics outcomes model representing both the human and hookworm populations in a high transmission region of Brazil. Experiments simulated different implementation scenarios of MDA and vaccination under varying circumstances. RESULTS: Considering only intervention costs, both annual MDA and vaccination were highly cost-effective (ICERs ≤ $790/DALY averted) compared to no intervention, with vaccination resulting in lower incremental cost-effectiveness ratios (ICERs ≤ $444/DALY averted). From the societal perspective, vaccination was economically dominant (i.e., less costly and more effective) versus annual MDA in all tested scenarios, except when vaccination was less efficacious (20% efficacy, 5 year duration) and MDA coverage was 75%. Increasing the vaccine's duration of protection and efficacy, and including a booster injection in adulthood all increased the benefits of vaccination (i.e., resulted in lower hookworm prevalence, averted more disability-adjusted life years, and saved more costs). Assuming its target product profile, a pediatric hookworm vaccine drastically decreased hookworm prevalence in children to 14.6% after 20 years, compared to 57.2% with no intervention and 54.1% with MDA. The addition of a booster in adulthood further reduced the overall prevalence from 68.0% to 36.0% and nearly eliminated hookworm infection in children. CONCLUSION: Using a human hookworm vaccine would be cost-effective and in many cases economically dominant, providing both health benefits and cost-savings. It could become a key technology in effecting control and elimination efforts for hookworm globally.
Authors: Nathan C Lo; Isaac I Bogoch; Brian G Blackburn; Giovanna Raso; Eliézer K N'Goran; Jean T Coulibaly; Sören L Becker; Howard B Abrams; Jürg Utzinger; Jason R Andrews Journal: Lancet Glob Health Date: 2015-10 Impact factor: 26.763
Authors: Wei Liu; Tom N McNeilly; Mairi Mitchell; Stewart T G Burgess; Alasdair J Nisbet; Jacqueline B Matthews; Simon A Babayan Journal: NPJ Vaccines Date: 2022-07-07 Impact factor: 9.399
Authors: Tara E Ness; Vedika Agrawal; Kathryn Bedard; Lara Ouellette; Timothy A Erickson; Peter Hotez; Jill E Weatherhead Journal: Am J Trop Med Hyg Date: 2020-11 Impact factor: 2.345
Authors: Tiffany Bouchery; Kara Filbey; Amy Shepherd; Jodie Chandler; Deepa Patel; Alfonso Schmidt; Mali Camberis; Adeline Peignier; Adam A T Smith; Karen Johnston; Gavin Painter; Mark Pearson; Paul Giacomin; Alex Loukas; Maria-Elena Bottazzi; Peter Hotez; Graham LeGros Journal: PLoS Pathog Date: 2018-03-22 Impact factor: 6.823
Authors: David J Diemert; Janaína Freire; Vanderson Valente; Carlo Geraldo Fraga; Frederico Talles; Shannon Grahek; Doreen Campbell; Amar Jariwala; Maria Victoria Periago; Martin Enk; Maria Flávia Gazzinelli; Maria Elena Bottazzi; Robert Hamilton; Jill Brelsford; Anna Yakovleva; Guangzhao Li; Jin Peng; Rodrigo Correa-Oliveira; Peter Hotez; Jeffrey Bethony Journal: PLoS Negl Trop Dis Date: 2017-05-02